+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
11 May 2021

DCGI – India approved anti-Covid drug 2-DG developed by DRDO for emergency use

/
Posted By
/
Comments0
/

The Drugs Controller General of India has approved an anti-COVID-19 drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) for emergency use, the Defence Ministry has said.

An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from COVID-19.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.